Gilead Sciences Inc.

7.08.2026 г., 20:06 ч. UTC

Gilead Sciences reports $65 million in revenue from Kymera Therapeutics collaboration, including a $45 million option exercise fee. Shares are higher despite earlier session pullback.

6.08.2026 г., 23:02 ч. UTC

Gilead Sciences filed a mixed securities shelf, raising investor concerns about share dilution. Shares are trading lower in after-market hours.

5.08.2026 г., 19:53 ч. UTC

Gilead Sciences shares are lower after reporting a $10.50 billion net loss and revising fiscal 2026 earnings guidance downward, despite strong HIV sales.

4.08.2026 г., 23:02 ч. UTC

Gilead Sciences reports a $10.50 billion net loss for Q2, lowering full-year GAAP EPS guidance. Shares are trading lower in after-market hours.

3.08.2026 г., 19:51 ч. UTC

Gilead Sciences advances following a California Supreme Court ruling on HIV drug innovation, boosting investor sentiment ahead of Q2 earnings report.

31.07.2026 г., 23:16 ч. UTC

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

30.07.2026 г., 21:31 ч. UTC

Gilead Sciences shares are lower in after-market hours, continuing a decline since Thursday's close and remaining below the 20-day moving average.

29.07.2026 г., 22:41 ч. UTC

Gilead Sciences Inc shares are lower in after-market trading, with no specific news identified to explain the decline amid notable volatility earlier in the session.

28.07.2026 г., 23:01 ч. UTC

Gilead Sciences received endorsement for Trodelvy with Keytruda for specific breast cancer patients, boosting shares modestly higher in after-market trading.

27.07.2026 г., 18:07 ч. UTC

Morgan Stanley maintains Overweight rating on Gilead Sciences, lowering price target to $165. Shares are higher since Friday, supported by positive news on Trodelvy.

24.07.2026 г., 21:41 ч. UTC

Gilead Sciences receives positive CHMP opinion for Trodelvy and Keytruda combination, with shares rising in after-market trading despite broader market volatility.

22.07.2026 г., 19:11 ч. UTC

Gilead Sciences Inc is gaining Wednesday, having pulled back earlier in the session. Broader market sentiment is influenced by rising crude oil prices and geopolitical tensions.

21.07.2026 г., 19:41 ч. UTC

Gilead Sciences shares are lower after Leerink Partners downgraded the stock to Market Perform and cut the price target to $127 from $146.

20.07.2026 г., 23:01 ч. UTC

Gilead Sciences shares are lower in after-market hours following a downgrade from Leerink Partners, citing challenges in the HIV prophylaxis market and revised sales outlook.

17.07.2026 г., 19:56 ч. UTC

Gilead Sciences shares are lower as the company missed full-year EPS estimates despite reporting $6.96 billion in revenue, reflecting heightened market volatility.

16.07.2026 г., 23:41 ч. UTC

Gilead Sciences Inc. shares moved higher in after-market trading, remaining above their 20-day moving average following three consecutive daily gains.

15.07.2026 г., 18:46 ч. UTC

Gilead Sciences Inc shares are higher, reflecting positive momentum in biotechnology amid a declining U.S. Dollar and easing inflation concerns.

14.07.2026 г., 23:16 ч. UTC

Gilead Sciences shares are higher in after-market trading, following a steady increase from earlier lows amid softer inflation data and a rally in Treasury bonds.

13.07.2026 г., 17:26 ч. UTC

Gilead Sciences is gaining as it prepares for key product launches in 2026, including Bulevirtide and a new HIV regimen under FDA review.

10.07.2026 г., 20:01 ч. UTC

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

9.07.2026 г., 19:36 ч. UTC

Gilead Sciences Inc's shares are lower despite regulatory achievements for Trodelvy and advancements in its HIV pipeline, reflecting broader market volatility.

8.07.2026 г., 23:51 ч. UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

7.07.2026 г., 23:02 ч. UTC

Gilead Sciences Inc. shares are lower in after-market hours, reflecting broader market declines amid rising geopolitical tensions and a widening U.S. trade deficit.

6.07.2026 г., 20:02 ч. UTC

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

2.07.2026 г., 22:56 ч. UTC

Gilead Sciences shares traded lower in after-market hours, with no specific news identified. Broader market mixed amid weaker U.S. jobless data.

1.07.2026 г., 19:14 ч. UTC

Gilead Sciences Inc. shares are lower today, reflecting routine performance within their one-month trading range despite stability around the midpoint.

30.06.2026 г., 20:07 ч. UTC

A social media post suggests bullish sentiment around Gilead Sciences, as a fund buys March call options. Shares are trading roughly flat in the session.

29.06.2026 г., 23:06 ч. UTC

Gilead Sciences Inc. shares are trading lower in after-market hours. Investor focus remains on upcoming U.S.-Iran talks that may impact market sentiment.

26.06.2026 г., 22:11 ч. UTC

Gilead Sciences Inc shares are lower in after-market hours, driven by notable declines in the Biotechnology sub-sector. No specific company news was identified.

25.06.2026 г., 23:56 ч. UTC

Gilead Sciences shares moved higher in after-market hours, despite earlier declines during regular trading amid mixed U.S. market performance influenced by economic data.